JP2021505551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021505551A5 JP2021505551A5 JP2020529491A JP2020529491A JP2021505551A5 JP 2021505551 A5 JP2021505551 A5 JP 2021505551A5 JP 2020529491 A JP2020529491 A JP 2020529491A JP 2020529491 A JP2020529491 A JP 2020529491A JP 2021505551 A5 JP2021505551 A5 JP 2021505551A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- solvate
- isomer
- hydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCNc1ccc(C)c(N)c1C(**=C)=O Chemical compound CCNc1ccc(C)c(N)c1C(**=C)=O 0.000 description 3
- OLLZXQIFCRIRMH-UHFFFAOYSA-N CCCC(NC)=O Chemical compound CCCC(NC)=O OLLZXQIFCRIRMH-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023151472A JP2023164604A (ja) | 2017-11-30 | 2023-09-19 | メイタンシノイド系薬物送達システム |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762593184P | 2017-11-30 | 2017-11-30 | |
| US62/593,184 | 2017-11-30 | ||
| PCT/US2018/063380 WO2019108975A1 (en) | 2017-11-30 | 2018-11-30 | Maytansinoid-based drug delivery systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151472A Division JP2023164604A (ja) | 2017-11-30 | 2023-09-19 | メイタンシノイド系薬物送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021505551A JP2021505551A (ja) | 2021-02-18 |
| JP2021505551A5 true JP2021505551A5 (https=) | 2023-05-15 |
| JP7442821B2 JP7442821B2 (ja) | 2024-03-05 |
Family
ID=64744962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529491A Active JP7442821B2 (ja) | 2017-11-30 | 2018-11-30 | メイタンシノイド系薬物送達システム |
| JP2023151472A Pending JP2023164604A (ja) | 2017-11-30 | 2023-09-19 | メイタンシノイド系薬物送達システム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023151472A Pending JP2023164604A (ja) | 2017-11-30 | 2023-09-19 | メイタンシノイド系薬物送達システム |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11572373B2 (https=) |
| EP (1) | EP3717018A1 (https=) |
| JP (2) | JP7442821B2 (https=) |
| KR (1) | KR20200117988A (https=) |
| CN (1) | CN111712263B (https=) |
| AU (1) | AU2018375788A1 (https=) |
| BR (1) | BR112020010989A2 (https=) |
| CA (1) | CA3083985A1 (https=) |
| IL (2) | IL274920B2 (https=) |
| MX (1) | MX2020005472A (https=) |
| WO (1) | WO2019108975A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6948708B2 (ja) | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| EP4344747A3 (en) | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
| CN110227164B (zh) | 2018-03-06 | 2021-11-23 | 江苏吉贝尔药业股份有限公司 | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 |
| JP2024546948A (ja) | 2021-12-15 | 2024-12-26 | ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド | コンジュゲート、それらの組成物、及びそれらの関連する方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125704A (en) | 1977-09-14 | 1978-11-14 | Sri International | Phenyl-substituted rubidazone analogs |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| NZ547370A (en) | 2003-12-04 | 2010-09-30 | Amr Technology Inc | Vinca derivatives |
| CN101743020A (zh) | 2007-05-16 | 2010-06-16 | Ktb肿瘤研究有限责任公司 | 低粘度蒽环制剂 |
| EP2289558A1 (en) | 2009-08-25 | 2011-03-02 | KTB Tumorforschungsgesellschaft mbH | Bisphosphonate-prodrugs |
| WO2012145112A2 (en) * | 2011-04-18 | 2012-10-26 | Immunogen, Inc. | Novel maytansinoid derivatives with sulfoxide linker |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| EP2630971B8 (en) | 2012-02-21 | 2017-12-13 | Vergell Medical S.A. | Combinations of albumin-based drug delivery systems |
| CA2891280C (en) * | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| CN104688740A (zh) | 2012-12-21 | 2015-06-10 | 百奥泰生物科技(广州)有限公司 | 类美登素衍生物及其制备方法和用途 |
| US20140221429A1 (en) | 2013-02-04 | 2014-08-07 | Saud Ibrahim Al-Resayes | Heterocyclic schiff's bases as novel and new antiglycation agents |
| EP3566750A3 (en) * | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| BR112017020149A8 (pt) * | 2015-03-27 | 2023-05-02 | Regeneron Pharma | Derivados de maitansinoide, conjugados dos mesmos e métodos de uso |
| WO2016205378A1 (en) | 2015-06-15 | 2016-12-22 | Abbott Diabetes Care Inc. | Stabilized lactate responsive enzymes, electrodes and sensors, and methods for making and using the same |
| JP6948708B2 (ja) * | 2015-06-19 | 2021-10-13 | センチュリオン バイオファーマ コーポレイション | 薬物制御放出のための送達系 |
| EP4344747A3 (en) | 2017-11-30 | 2024-07-03 | LadRx Corporation | Albumin-binding prodrugs of auristatin e derivatives |
-
2018
- 2018-11-30 AU AU2018375788A patent/AU2018375788A1/en not_active Abandoned
- 2018-11-30 IL IL274920A patent/IL274920B2/en unknown
- 2018-11-30 IL IL305268A patent/IL305268A/en unknown
- 2018-11-30 MX MX2020005472A patent/MX2020005472A/es unknown
- 2018-11-30 JP JP2020529491A patent/JP7442821B2/ja active Active
- 2018-11-30 US US16/768,418 patent/US11572373B2/en active Active
- 2018-11-30 BR BR112020010989-4A patent/BR112020010989A2/pt not_active Application Discontinuation
- 2018-11-30 CN CN201880088076.0A patent/CN111712263B/zh active Active
- 2018-11-30 CA CA3083985A patent/CA3083985A1/en active Pending
- 2018-11-30 KR KR1020207018379A patent/KR20200117988A/ko not_active Ceased
- 2018-11-30 EP EP18822213.7A patent/EP3717018A1/en active Pending
- 2018-11-30 WO PCT/US2018/063380 patent/WO2019108975A1/en not_active Ceased
-
2022
- 2022-12-21 US US18/086,076 patent/US20230391794A1/en not_active Abandoned
-
2023
- 2023-09-19 JP JP2023151472A patent/JP2023164604A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021505551A5 (https=) | ||
| RU2018144315A (ru) | КОНЪЮГАТЫ АНТИТЕЛА К cMet И ЛЕКАРСТВЕННОГО СРЕДСТВА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| ES2909486T3 (es) | Sistemas de administración para liberación controlada de fármaco | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| BR112020023975A2 (pt) | composições que compreendem os compostos de bisfluoroalquil-1,4-benzodiazepinona e imunoterapêuticos e métodos de uso das mesmas | |
| JP2021505541A5 (https=) | ||
| RU2015156499A (ru) | Конъюгаты антитела с лекарственным средством | |
| JP2023527962A5 (https=) | ||
| AU2018375787A1 (en) | Albumin-binding prodrugs of auristatin E derivatives | |
| BR112021008781A2 (pt) | combinação de inibidores de cd-47 de pequena molécula com outros agentes anticâncer | |
| ES2542861T3 (es) | Composiciones farmacéuticas capaces de inducir la apoptosis en células tumorales, útiles para el diagnóstico y tratamiento de leucemia linfocítica crónica-B | |
| BR112020018555A2 (pt) | Método de modulação das vias de sinalização de tigit e pd-1 usando compostos de 1,2,4-oxadiazol | |
| JP2022533020A (ja) | がん免疫療法アジュバント | |
| RU2697551C2 (ru) | Новые производные peg | |
| TWI832069B (zh) | 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物 | |
| KR102694803B1 (ko) | A-노르-5α안드로스테인 화합물계 약물 및 항암제의 병용 | |
| KR20190103258A (ko) | 뼈 또는 혈액 암의 치료를 위한 치료제로서의 포스파플라틴 화합물 | |
| PT1812797E (pt) | Composições e métodos para o tratamento e prevenção de doenças hiperproliferativas | |
| RU2020121456A (ru) | Системы доставки лекарств на основе майтанзиноида | |
| JP2016104703A (ja) | 抗腫瘍剤 | |
| BR112023000351B1 (pt) | Uso de uma combinação compreendendo a combinação de dunniona como composto á base de naftoquinona com inibidores de checkpoint imunológico e indutores de morte celular imunogênica para o tratamento de câncer | |
| BR122024023391A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica |